These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 24077285

  • 1. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, Kesari S, Boothman DA, Habib AA.
    Oncogene; 2014 Aug 14; 33(33):4253-64. PubMed ID: 24077285
    [Abstract] [Full Text] [Related]

  • 2. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
    Li L, Puliyappadamba VT, Chakraborty S, Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P, Burma S, Boothman DA, Habib AA.
    Oncogene; 2015 Jan 02; 34(1):129-134. PubMed ID: 24362532
    [Abstract] [Full Text] [Related]

  • 3. Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch.
    Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, Mickey B, Noorani S, Shu HK, Burma S, Boothman DA, Habib AA.
    Cell Rep; 2013 Aug 29; 4(4):764-75. PubMed ID: 23972990
    [Abstract] [Full Text] [Related]

  • 4. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L, Shen D, Liang D, Shi J, Song C, Jiang K, Menglin Ren, Du S, Cheng W, Ma J, Li S, Bi X, Barr MP, Fang Z, Xu Q, Li W, Piao H, Meng S.
    Cancer Lett; 2020 Nov 28; 493():156-166. PubMed ID: 32860853
    [Abstract] [Full Text] [Related]

  • 5. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.
    Cancer Res; 2006 Jan 15; 66(2):867-74. PubMed ID: 16424019
    [Abstract] [Full Text] [Related]

  • 6. Formation of EGFRwt/EGFRvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy.
    Jahnke K, Struve N, Hofmann D, Gote MJ, Bach M, Kriegs M, Hausmann M.
    Nanoscale; 2024 Aug 15; 16(32):15240-15255. PubMed ID: 39073345
    [Abstract] [Full Text] [Related]

  • 7. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
    Lo HW, Cao X, Zhu H, Ali-Osman F.
    Mol Cancer Res; 2010 Feb 15; 8(2):232-45. PubMed ID: 20145033
    [Abstract] [Full Text] [Related]

  • 8. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).
    Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD.
    Biochem J; 1997 Jun 15; 324 ( Pt 3)(Pt 3):855-61. PubMed ID: 9210410
    [Abstract] [Full Text] [Related]

  • 9. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL.
    Proc Natl Acad Sci U S A; 2011 Sep 20; 108(38):15984-9. PubMed ID: 21896743
    [Abstract] [Full Text] [Related]

  • 10. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 11. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.
    Zhan Y, O'Rourke DM.
    Cancer Res; 2004 Nov 15; 64(22):8292-8. PubMed ID: 15548697
    [Abstract] [Full Text] [Related]

  • 12. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G, Narayan RN, Horton L, Patel TR, Habib AA.
    Curr Cancer Drug Targets; 2017 Nov 15; 17(3):297-302. PubMed ID: 28004613
    [Abstract] [Full Text] [Related]

  • 13. ERK-mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells.
    Haryuni RD, Tanaka T, Zhou Y, Yokoyama S, Sakurai H.
    Oncol Lett; 2020 Sep 15; 20(3):2477-2482. PubMed ID: 32782566
    [Abstract] [Full Text] [Related]

  • 14. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z, Jia X, Jiang T, Zhang J, Li X, Kang C, Ren H.
    Neuro Oncol; 2014 Sep 15; 16(9):1229-43. PubMed ID: 24861878
    [Abstract] [Full Text] [Related]

  • 15. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N.
    J Exp Clin Cancer Res; 2019 Jun 18; 38(1):266. PubMed ID: 31215502
    [Abstract] [Full Text] [Related]

  • 16. EGFRvIII-mediated radioresistance through a strong cytoprotective response.
    Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, Dent P, Schmidt-Ullrich RK.
    Oncogene; 2003 Aug 28; 22(36):5545-53. PubMed ID: 12944901
    [Abstract] [Full Text] [Related]

  • 17. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.
    Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA.
    Cancer Cell; 2013 Oct 14; 24(4):438-49. PubMed ID: 24135280
    [Abstract] [Full Text] [Related]

  • 18. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.
    J Neurooncol; 2011 May 14; 102(3):353-66. PubMed ID: 20938717
    [Abstract] [Full Text] [Related]

  • 19. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD.
    J Neurooncol; 2018 Jul 14; 138(3):489-498. PubMed ID: 29564747
    [Abstract] [Full Text] [Related]

  • 20. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
    Wei JW, Cui JQ, Zhou X, Fang C, Tan YL, Chen LY, Yang C, Liu M, Kang CS.
    Cancer Lett; 2016 Sep 28; 380(1):1-9. PubMed ID: 27317648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.